The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy
Clinical News

The Lancet: Russian Coronavirus Sputnik V Vaccine Achieves Over 90% Efficacy

Russia’s Sputnik V vaccine was 91.6% effective in preventing people from developing Covid-19, according to peer-reviewed results from its late-stage clinical trial published yesterday in The Lancet international medical journal.…
EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease
Clinical News

EMA Accepts MAA For Oxbryta To Treat Haemolytic Anaemia In Sickle Cell Disease

The European Medicines Agency (EMA) has accepted Global Blood Therapeutics (GBT) marketing authorisation application (MAA) for Oxbryta® (voxelotor) for the treatment of haemolytic anaemia in sickle cell disease (SCD). According to the company,…
TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed
NOVITÀ

TIF Updated Vaccinations & Therapeutic Drugs COVID-19 Guide Has Landed

A comprehensive Guide for both existing and developing vaccines and treatments against COVID-19, exclusively developed by TIF for its global thalassaemia community. Featuring: Pfizer, Moderna, AstraZeneca: What are the differencies…
WHO Maintains Official Relations With TIF For 2021-2024
NOVITÀ

WHO Maintains Official Relations With TIF For 2021-2024

We are very proud to inform you that TIF remains in official relations with the World Health Organization (WHO) for 2021-2024 The extension of ΤIF’s official relations with WHO was…
Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy
Clinical News

Clinical Trial Cleared for GPH101: The First Potentially Curative Sickle Cell Disease Therapy

The U.S. Food & Drug Administration (FDA) has cleared an investigational new drug (IND) application for the experimental gene editing therapy GPH101 by Graphite Bio to initiate a Phase 1/2…
Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic
NOVITÀ

Blood Supply Challenges & Transfusion Care of Patients With Haemoglobinopathies During COVID-19 Pandemic

The COVID-19 pandemic has had an impact on blood supply in several countries, jeopardizing the already demanding and often suboptimal care for haemoglobinopathies patients, mainly in developing and low-income countries…
EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia
NOVITÀ

EdiGene Announces Approval in China of its IND Application for CRISPR/Cas 9 Gene Editing Therapy ET-01 in β-thalassaemia

The Center for Drug Evaluation (CDE) of China‘s National Medical Products Administration (NMPA) has recently approved EdiGene’s application for ET-01, an investigational CRISPR-Cas9 gene editing therapy for patients with transfusion dependent β-thalassaemia. This marks the first…
Back to top button